Unknown

Dataset Information

0

Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.


ABSTRACT: Poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PARP proteins. Optimization of our lead compound 1 (( Z)-2-benzylidene-3-oxo-2,3-dihydrobenzofuran-7-carboxamide; PARP-1 IC50 = 434 nM) led to a tetrazolyl analogue (51, IC50 = 35 nM) with improved inhibition. Isosteric replacement of the tetrazole ring with a carboxyl group (60, IC50 = 68 nM) gave a promising new lead, which was subsequently optimized to obtain analogues with potent PARP-1 IC50 values (4-197 nM). PARP enzyme profiling revealed that the majority of compounds are selective toward PARP-2 with IC50 values comparable to clinical inhibitors. X-ray crystal structures of the key inhibitors bound to PARP-1 illustrated the mode of interaction with analogue appendages extending toward the PARP-1 adenosine-binding pocket. Compound 81, an isoform-selective PARP-1/-2 (IC50 = 30 nM/2 nM) inhibitor, demonstrated selective cytotoxic effect toward breast cancer gene 1 ( BRCA1)-deficient cells compared to isogenic BRCA1-proficient cells.

SUBMITTER: Velagapudi UK 

PROVIDER: S-EPMC7378964 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.

Velagapudi Uday Kiran UK   Langelier Marie-France MF   Delgado-Martin Cristina C   Diolaiti Morgan E ME   Bakker Sietske S   Ashworth Alan A   Patel Bhargav A BA   Shao Xuwei X   Pascal John M JM   Talele Tanaji T TT  

Journal of medicinal chemistry 20190524 11


Poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PARP proteins. Optimization of our lead compound 1 (( Z)-2-benzylidene-3-oxo-2,3-dihydrobenzofuran-7-carboxamide; PARP-1 IC<sub>50</sub> = 434 nM) led to a tetrazolyl analogue (51, IC<sub>50</sub> = 35 nM) with improved inhibition. Isosteric replacement of the tetrazole ring with a carboxyl group (60, IC<sub>50</sub> = 68 nM) gave a promising new lead, which was  ...[more]

Similar Datasets

| S-EPMC4094269 | biostudies-literature
| S-EPMC4207131 | biostudies-literature
| S-EPMC4538820 | biostudies-literature
| S-EPMC5934274 | biostudies-literature
| S-EPMC8142146 | biostudies-literature
| S-EPMC6572064 | biostudies-literature
| S-EPMC6089346 | biostudies-literature
| S-EPMC2602769 | biostudies-literature
| S-EPMC1563857 | biostudies-literature
| S-EPMC4334965 | biostudies-literature